Federal Reserve

  • Most Popular
  • Most Shared

REUTERS SHOWCASE

Monsoon Floods

Monsoon Floods

Death toll in Uttarakhand monsoon floods crosses 150  Full Article 

Auto Market

Auto Market

Tata Motors upgrades cars as rivals launch new ones.  Full Article 

EU Fines Ranbaxy

EU Fines Ranbaxy

EU fines Ranbaxy, others for blocking cheaper drugs.  Full Article 

Business Optimism

Business Optimism

Asian businesses optimistic; sentiment in India falls.  Full Article 

Financing Trouble

Financing Trouble

U.S. court lets stand Ex-Im Bank loan for Air India.  Full Article 

Euro Economy

Euro Economy

Half-way to lost decade, Europe's growth task as tough as ever.  Full Article 

Buy, Sell or Hold?

Buy, Sell or Hold?

Confused while buying stocks? Get buy, sell or hold recommendations from VantageTrade.  Full Coverage 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage 

MARKET EYE-Pharma stocks fall on speculation over pricing policy

Related Topics

Stocks

   

Thu Nov 22, 2012 2:47pm IST

* Shares in Indian drugmakers fall on speculation the
government's final decision on the pricing policy for the sector
might be more disruptive than expected.
* Local media reports suggest a panel of ministers has agreed to
settle on a market-based pricing mechanism, as expected, but
capping drug prices at a simple average price of brands as
opposed to the initial proposal of using a weighted average. link.reuters.com/jur24t
* The proposal, if finalised, would be "incrementally negative"
for the sector, but the impact would vary from company to
company, Nomura says in a note on Thursday.
* The new proposal is likely to be more negative for Dr Reddy's
, Glenmark and Cadila Healthcare,
Nomura says. 
* Cipla falls 0.1 percent, while Ranbaxy Laboratories
 is down 0.9 percent. 
* Dr Reddy's Laboratories is flat, Glenmark Pharmaceuticals is
up 3.9 percent and Cadila gains 2.2 percent.

 (abhishek.vishnoi@thomsonreuters.com /;
abhishek.vishnoi.reuters.com@reuters.net/kaustubh.kulkarni@thoms
onreuters.com /; kaustubh.kulkarni.reuters.com@reuters.net)
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.